MEXOM · Development and characterization of extracellular vesicles an innovative cell-free therapeutical product for treatment of stroke
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2018-09-03 → 2021-11-05
- Финансиране от ЕС
- 160 800 €
- Участници
- 2
- Схема
- MSCA-IF-EF-SE
Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.
Накратко на български
Екстракцията на малки биологични частици от стволови клетки на пъповина се изследва като средство за спиране на възпаленията в мозъка след инсулт. Това е важно, защото настоящите терапии са ограничени, а инсултите причиняват тежка инвалидност и висока смъртност в Европа.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Development and characterization of extracellular vesicles an innovative cell-free therapeutical product for treatment of stroke
Stroke is serious life-threatening but unmet medical condition. It is the second leading cause of long-term disability in Europe and is the sixth leading cause worldwide. In the EU, the annual economic cost of stroke is an estimated €27 billion. Current stroke therapy is mainly based on general care and rehabilitation. 10-35% of stroke patients in Europe die within 28-30 days. Most strokes are caused by brain ischemia when blood vessel gets blocked, brain cells because of lack of oxygen get damaged and die. Microglia, brain immune cells, are the key cells initiating neuroinflammation in the injured brain area that evolves into amplifying brain inflammatory responses eventually leading to the secondary much worse brain damage. Mesenchymal stromal cells (MSCs) are specific cells found in human umbilical cord that is usually discarded as medical waste. The cord tissues for this project were obtained from the 'Biobank Antwerpen' in Belgium, provided by the donors upon written informed consent. These cells can be isolated in the laboratory and secrete so called extracellular vesicles (MSC-EVs). The latter are very small, nano size biological particles containing many different types of therapeutically active molecules. During the last years, accumulating evidence show that MSC-EVs can stop brain inflammation and, on the top of that, start regeneration of already occurred brain damage in animal models. However, most of these studies produced MSC-EVs not according to the strict Good Manufacturing Practice (GMP) requirements applicable for medicinal drugs which is a must to be used on humans. The Host of the project is Exo Biologics company located in Belgium, which is one of the pioneers in EVs field. The company has developed a proprietary and unique, fully GMP-compliant MSC-EVs production platform. Based on the mentioned state-of-the-art knowledge and unmet medical needs, MEXOM project's key aim was to develop and characterize at the Host’s laboratories an innovative MSC-EVs therapeutical product for treatment of stroke. The key objectives of MEXOM project were successfully achieved. Firstly, a novel early-stage MSC-EVs drug candidate for stroke was developed, and its features were described. Secondly, its strong potential to inhibit brain inflammation was demonstrated in the laboratory. Eventually, a hypothesis how this drug works in stroke was formulated.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Stroke is leading cause of long-term disability in Europe and worldwide with no effective treatment so far. Inflammation plays a vital role in brain’s response to ischemic stroke with deleterious consequences during early acute phase. Strong immunomodulatory effect of human mesenchymal stem cell (MSCs) demonstrated in many preclinical stroke models, however, has failed in clinical experiments. Recent preclinical data indicate that MSCs exert their anti-inflammatory effects via secreted extracellular vesicles (EVs) through microRNAs and this potential could be boosted by preconditioning MSCs ex vivo with small molecules. The aim of this Fellowship will be the determination of MSC-EVs anti-inflammatory mechanism of action specific for stroke for the first time.The Host has developed clinical-grade technology (GLP/GMP) for human cord MSC-EVs manufacturing at large scale with anti-inflammatory action. During this Project the Researcher will receive training-through-research and will investigate the small molecule potential impact on MSC-EVs cargo enrichment with specific microRNAs. Then he will study candidate microRNAs anti-inflammatory potential in vitro on the key brain inflammation cells. The Researcher will acquire transferable knowledge in regulations, quality assurance, intellectual property and entrepreneurship. Novel competences will reinforce the Researcher as mature and independent scientist in the field of regenerative medicine with new career opportunities in private sector. Communication and dissemination will be carried out with all stakeholders, including academia, industry, civil societies, policymakers and general public.The Researcher will transfer his molecular biology knowledge and skills, thus advancing the development of MSC-EVs product for treatment of stroke at the Host towards clinically applicable commercial innovation. This Fellowship will highlight Europe as world leader in innovations targeting unmet medical needs.
Оригинален текст от CORDIS (на английски).
Участници
Връзки
Данни: CORDIS, © Европейски съюз